187 related articles for article (PubMed ID: 11818148)
1. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein.
Wierzbicki A; Kiszka I; Kaneko H; Kmieciak D; Wasik TJ; Gzyl J; Kaneko Y; Kozbor D
Vaccine; 2002 Jan; 20(9-10):1295-307. PubMed ID: 11818148
[TBL] [Abstract][Full Text] [Related]
2. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
[TBL] [Abstract][Full Text] [Related]
3. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
5. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
6. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
8. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
Belyakov IM; Wyatt LS; Ahlers JD; Earl P; Pendleton CD; Kelsall BL; Strober W; Moss B; Berzofsky JA
J Virol; 1998 Oct; 72(10):8264-72. PubMed ID: 9733870
[TBL] [Abstract][Full Text] [Related]
9. Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.
Megati S; Garcia-Hand D; Cappello S; Roopchand V; Masood A; Xu R; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Smith LR; Eldridge JH; Sidhu MK; Egan MA
Vaccine; 2008 Sep; 26(40):5083-94. PubMed ID: 18485543
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
Sharpe S; Hanke T; Tinsley-Bown A; Dennis M; Dowall S; McMichael A; Cranage M
Virology; 2003 Aug; 313(1):13-21. PubMed ID: 12951017
[TBL] [Abstract][Full Text] [Related]
11. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
Gherardi MM; Ramírez JC; Esteban M
J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
[TBL] [Abstract][Full Text] [Related]
13. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens.
Gherardi MM; Ramírez JC; Esteban M
Histol Histopathol; 2001 Apr; 16(2):655-67. PubMed ID: 11332721
[TBL] [Abstract][Full Text] [Related]
14. M cell DNA vaccination for CTL immunity to HIV.
Wang X; Hone DM; Haddad A; Shata MT; Pascual DW
J Immunol; 2003 Nov; 171(9):4717-25. PubMed ID: 14568947
[TBL] [Abstract][Full Text] [Related]
15. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
[TBL] [Abstract][Full Text] [Related]
16. Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.
Thippeshappa R; Tian B; Cleveland B; Guo W; Polacino P; Hu SL
Clin Vaccine Immunol; 2015 Dec; 23(3):204-12. PubMed ID: 26718849
[TBL] [Abstract][Full Text] [Related]
17. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
Naito T; Kaneko Y; Kozbor D
J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
[TBL] [Abstract][Full Text] [Related]
19. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.
Khattar SK; Samal S; Devico AL; Collins PL; Samal SK
J Virol; 2011 Oct; 85(20):10529-41. PubMed ID: 21849467
[TBL] [Abstract][Full Text] [Related]
20. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
